Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported revenue was CNY 33,432.31 million compared to CNY 27,600.24 million a year ago. Net loss was CNY 187.4 million compared to net income of CNY 176.14 million a year ago.

Basic loss per share from continuing operations was CNY 0.038 compared to basic earnings per share from continuing operations of CNY 0.036 a year ago. Diluted loss per share from continuing operations was CNY 0.038 compared to diluted earnings per share from continuing operations of CNY 0.036 a year ago.